Clinical Trial Update: ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ECX + panitumumab versus ECX alone in locally advanced gastric cancer or cancer of the gastroesophageal junction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Neoplasms
• Stomach Neoplasms

Drugs mentioned

• ECX
• Panitumumab (panitumumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Stomach Neoplasms, Gastroesophageal Junction Neoplasms | Phase 2 | Status: COMPLETED